May 2024 Spotlight On Euronext Paris Growth Companies With High Insider Ownership

Amid a backdrop of fluctuating European markets, with France's CAC 40 Index experiencing a modest decline, investors continue to seek stable yet promising opportunities. In this context, growth companies on the Euronext Paris with high insider ownership may offer a compelling narrative due to the alignment of interests between company management and shareholders, potentially fostering robust governance and resilience in uncertain economic times.

Top 10 Growth Companies With High Insider Ownership In France

Name	Insider Ownership	Earnings Growth
VusionGroup (ENXTPA:VU)	13.5%	24.4%
Groupe OKwind Société anonyme (ENXTPA:ALOKW)	24.8%	30.6%
WALLIX GROUP (ENXTPA:ALLIX)	19.8%	101.4%
La Française de l'Energie (ENXTPA:FDE)	20.1%	37.7%
Adocia (ENXTPA:ADOC)	12.4%	104.5%
OSE Immunotherapeutics (ENXTPA:OSE)	24.9%	92.9%
Icape Holding (ENXTPA:ALICA)	30.2%	26.1%
Arcure (ENXTPA:ALCUR)	21.4%	41.7%
Munic (ENXTPA:ALMUN)	29.2%	150%
MedinCell (ENXTPA:MEDCL)	16.4%	68.8%

Click here to see the full list of 21 stocks from our Fast Growing Euronext Paris Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Believe

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Believe S.A. offers digital music services to independent labels and artists across regions including France, Germany, Europe, the Americas, Asia, and Oceania, with a market capitalization of approximately €1.49 billion.

Operations: The company generates revenue primarily through Premium Solutions, which brought in €825.12 million, and Automated Solutions, contributing €55.19 million.

Insider Ownership: 10.9%

Earnings Growth Forecast: 74.2% p.a.

Believe S.A., a French digital music company, has recently been the subject of acquisition interest, notably rejecting a €1.65 billion offer from Warner Music Group while favoring an internal consortium's lower bid. This highlights strong insider commitment to the company's autonomy and future direction. Despite reporting a significant reduction in net loss from €29.76 million to €5.48 million year-over-year and forecasting revenue growth at 14% annually, Believe's profitability is expected only in the next three years with modest earnings growth projected at 74.2% per annum, slightly below broader market expectations.

• Navigate through the intricacies of Believe with our comprehensive analyst estimates report here.

• Insights from our recent valuation report point to the potential undervaluation of Believe shares in the market.

ENXTPA:BLV Earnings and Revenue Growth as at May 2024

Lectra

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lectra SA offers industrial intelligence solutions across fashion, automotive, and furniture sectors with a market capitalization of approximately €1.23 billion.

Operations: The company generates revenue primarily from the Americas and Asia-Pacific regions, totaling €170.33 million and €110.28 million respectively.

Insider Ownership: 19.6%

Earnings Growth Forecast: 28.6% p.a.

Lectra SA, a French technology firm, recorded a slight dip in net income to €7.17 million from €7.63 million year-over-year, despite an increase in sales to €129.56 million. The company is trading at 21% below its estimated fair value and shows promising growth forecasts with earnings expected to rise by 28.6% annually and revenue projected to grow at 11.3% per year, outpacing the French market's 5.7%. However, its Return on Equity is anticipated to remain low at 13.3%.

• Click here to discover the nuances of Lectra with our detailed analytical future growth report.

• Our valuation report unveils the possibility Lectra's shares may be trading at a discount.

ENXTPA:LSS Ownership Breakdown as at May 2024

MedinCell

Simply Wall St Growth Rating: ★★★★★☆

Overview: MedinCell S.A. is a French pharmaceutical company specializing in the development of long-acting injectable medications across various therapeutic areas, with a market capitalization of approximately €440.48 million.

Operations: The company generates its revenue primarily from the pharmaceuticals segment, totaling €14.13 million.

Insider Ownership: 16.4%

Earnings Growth Forecast: 68.8% p.a.

MedinCell, a French biotech firm, is leveraging its proprietary BEPO® technology to develop long-acting injectable treatments, showing promise despite recent setbacks. The company's collaboration with major industry players like Teva and AbbVie underscores its innovative approach, with significant financial backing evident from a $35 million upfront payment from AbbVie and potential milestones reaching up to €1.9 billion. Although MedinCell's F14 trial did not meet its primary endpoint, improvements in secondary measures suggest potential in niche applications. Trading at 67.5% below its fair value and expected to turn profitable within three years, the company is poised for rapid revenue growth at 40.1% annually—substantially outpacing the broader French market's 5.7%.

• Unlock comprehensive insights into our analysis of MedinCell stock in this growth report.

• Our valuation report unveils the possibility MedinCell's shares may be trading at a premium.

ENXTPA:MEDCL Ownership Breakdown as at May 2024

Turning Ideas Into Actions

• Discover the full array of 21 Fast Growing Euronext Paris Companies With High Insider Ownership right here.

• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.

• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ENXTPA:BLV ENXTPA:LSS and ENXTPA:MEDCL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com